STAAR Surgical Co (STAA) stock
Close on Nov 11, 2026Market cap $1.34BP/E –Yield –
STAAR Surgical Co grew revenue 42.4% to $328.27M over the twelve months to Oct 2, 2026. Free cash flow was $17.85M. At the latest close the market valued the company at $1.34B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Oct 2, 2026
Valuation
- Market cap
- $1.34B
- P/E ratio
- –
- Price to sales
- 4.08
- Price to book
- 3.56
- Dividend yield
- –
- Free cash flow yield
- 1.33%
Fundamentals
- Revenue
- $328.27M
- Net income
- $530.00K
- EPS, diluted
- $0.00
- Free cash flow
- $17.85M
- Book value per share
- $7.31
- Diluted shares
- 51M
Trading
- Next earnings
- Mar 2, 2027 (estimated, after the close)
- Previous close
- $23.87
- Open
- $23.79
- Day's range
- $23.79 – $26.77
- Volume
- 939,991
- Average volume (20 days)
- 798,671
- Index membership
- S&P SmallCap 600 (since Aug 2023), Russell 2000, Russell 3000
- Beta (5 years)
- 1.48
- 52-week range
- $15.59 – $35.87
- RSI (14 days)
- 62.3
- Volatility (1 year)
- 57.2%
- Relative volume
- 1.01×
- WACC
- 12.3%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | STAA | S&P 500 | Difference | STAA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.2% | -2.4% | +25.6 pts | ||
| 3 months | +7.0% | -1.2% | +8.2 pts | ||
| Year to date | +15.6% | +12.3% | +3.3 pts | ||
| 1 year | -2.6% | +12.4% | −15.0 pts | ||
| 3 years | -20.3% | +78.8% | −99.1 pts | -7.3% | +21.4% |
| 5 years | -76.4% | +75.2% | −151.6 pts | -25.1% | +11.9% |
| 10 years | +151.8% | +311.1% | −159.3 pts | +9.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases STAAR Surgical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About STAAR Surgical
Ophthalmic Goods
STAAR Surgical Company designs, manufactures, and markets implantable lenses and delivery systems for ophthalmic surgery, specializing in phakic intraocular lenses used in refractive eye care. Its principal offerings comprise the EVO family of Implantable Collamer Lenses (ICLs), which include models such as EVO, EVO+, EVO Visian, and EVO Viva, designed to correct refractive vision conditions including myopia, astigmatism, and presbyopia without removing corneal tissue. The company sells its vision correction solutions globally to ophthalmic surgeons and patients seeking alternatives to eyeglasses or contact lenses.
Company profile, executives and historySTAAR Surgical stock: common questions
What is STAAR Surgical's stock price?
STAA closed at $26.69 on Nov 11, 2026, up 11.81% on the day. Over the past 52 weeks it traded between $15.59 and $35.87.
What is STAAR Surgical's market cap?
STAAR Surgical was worth $1.34B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is STAA's P/E ratio?
STAAR Surgical lost money over the twelve months to Oct 2, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does STAAR Surgical make?
STAAR Surgical reported revenue of $328.27M for the twelve months to Oct 2, 2026, up 42.4% from a year earlier.
Does STAAR Surgical pay a dividend?
No. STAAR Surgical has not paid a cash dividend over the last twelve months.
When does STAAR Surgical report earnings next?
STAAR Surgical is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has STAA stock performed over the past year?
Including dividends, STAA returned -2.6% over the past year, against +12.4% for the S&P 500.
Who are STAAR Surgical's competitors?
Companies most similar to STAAR Surgical by business, industry and size include RXST, COO, WRBY, ALC, BLCO.
See a number that looks wrong?